Universe Pharmaceuticals INC EBIT

Universe Pharmaceuticals INC (UPC) currently reports a EBIT of $-480K as of March 2026. That compares with $-26M in the prior-year period — up 98.1% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Universe Pharmaceuticals INC's EBIT history and peer comparisons.

Universe Pharmaceuticals INC's EBIT increased from $-26M to $-480K — a 98.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Universe Pharmaceuticals INC's EBIT of $-480K is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Universe Pharmaceuticals INC reported $-480K in EBIT as of March 2026. That compares with $-26M in the prior-year period — up 98.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-480K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Universe Pharmaceuticals INC, and consider following UPC for alerts when major investors trade the stock.